Business Description
Yifan Pharmaceutical Co Ltd
ISIN : CNE000001K65
Share Class Description:
SZSE:002019: Class ACompare
Compare
Traded in other countries / regions
002019.China IPO Date
2004-07-13Description
Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.43 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | -4.57 | |||||
| Interest Coverage | 5.54 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.21 | |||||
| Beneish M-Score | -2.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9 | |||||
| 3-Year Book Growth Rate | -0.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 22.34 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.22 | |||||
| 9-Day RSI | 67.72 | |||||
| 14-Day RSI | 64.17 | |||||
| 6-1 Month Momentum % | -4.46 | |||||
| 12-1 Month Momentum % | -6.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.32 | |||||
| Quick Ratio | 0.96 | |||||
| Cash Ratio | 0.36 | |||||
| Days Inventory | 136.64 | |||||
| Days Sales Outstanding | 90.76 | |||||
| Days Payable | 63.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.8 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| Forward Dividend Yield % | 0.8 | |||||
| 5-Year Yield-on-Cost % | 0.78 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 0.5 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.07 | |||||
| Operating Margin % | 7.78 | |||||
| Net Margin % | -6.64 | |||||
| FCF Margin % | -1.49 | |||||
| ROE % | -3.88 | |||||
| ROA % | -2.76 | |||||
| ROIC % | 4.2 | |||||
| 3-Year ROIIC % | -303.04 | |||||
| ROC (Joel Greenblatt) % | -17.45 | |||||
| ROCE % | -5.75 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 20.33 | |||||
| PE Ratio without NRI | 27.08 | |||||
| Shiller PE Ratio | 24.63 | |||||
| PS Ratio | 3.11 | |||||
| PB Ratio | 1.83 | |||||
| Price-to-Tangible-Book | 4.91 | |||||
| Price-to-Operating-Cash-Flow | 35.31 | |||||
| EV-to-EBIT | -31.33 | |||||
| EV-to-EBITDA | -31.33 | |||||
| EV-to-Revenue | 3.44 | |||||
| EV-to-FCF | -228.4 | |||||
| Price-to-Projected-FCF | 2.38 | |||||
| Price-to-Median-PS-Value | 0.73 | |||||
| Price-to-Graham-Number | 2.43 | |||||
| Price-to-Net-Current-Asset-Value | 213 | |||||
| Earnings Yield (Greenblatt) % | -3.19 | |||||
| FCF Yield % | -0.47 | |||||
| Forward Rate of Return (Yacktman) % | -37.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Yifan Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 4,996.037 | ||
| EPS (TTM) (Â¥) | -0.27 | ||
| Beta | 1.56 | ||
| Volatility % | 54.38 | ||
| 14-Day RSI | 64.17 | ||
| 14-Day ATR (Â¥) | 0.482321 | ||
| 20-Day SMA (Â¥) | 12.2785 | ||
| 12-1 Month Momentum % | -6.99 | ||
| 52-Week Range (Â¥) | 9.11 - 16.86 | ||
| Shares Outstanding (Mil) | 1,216.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Yifan Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Yifan Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Yifan Pharmaceutical Co Ltd Frequently Asked Questions
What is Yifan Pharmaceutical Co Ltd(SZSE:002019)'s stock price today?
The current price of SZSE:002019 is ¥12.81. The 52 week high of SZSE:002019 is ¥16.86 and 52 week low is ¥9.11.
When is next earnings date of Yifan Pharmaceutical Co Ltd(SZSE:002019)?
The next earnings date of Yifan Pharmaceutical Co Ltd(SZSE:002019) is .
Does Yifan Pharmaceutical Co Ltd(SZSE:002019) pay dividends? If so, how much?
The Dividend Yield %  of Yifan Pharmaceutical Co Ltd(SZSE:002019) is 0.8% (As of Today), Highest Dividend Payout Ratio of Yifan Pharmaceutical Co Ltd(SZSE:002019) was 0.67. The lowest was 0.06. And the median was 0.15. The  Forward Dividend Yield % of Yifan Pharmaceutical Co Ltd(SZSE:002019) is 0.8%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers